- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06568939
En studie for å vurdere uønskede hendelser og hvordan intravenøst (IV) infundert Telisotuzumab Vedotin (ABBV-399) beveger seg gjennom kroppen som monoterapi hos voksne deltakere med tidligere behandlet ikke-plateepitel, ikke-småcellet lungekreft (NSCLC)
En fase 2, åpen, randomisert, global studie av to Telisotuzumab Vedotin-regimer hos forsøkspersoner med tidligere behandlet c-Met-overuttrykk, EGFR villtype, lokalt avansert/metastatisk ikke-plateepitel, ikke-småcellet lungekreft
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-post: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
-
São Paulo, Brasil, 01323-020
- Rekruttering
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza, Ceará, Brasil, 60810-180
- Rekruttering
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80510-130
- Rekruttering
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém, Pará, Brasil, 66063-495
- Rekruttering
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife, Pernambuco, Brasil, 50040-000
- Rekruttering
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasil, 59075-740
- Rekruttering
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasil, 98700-000
- Rekruttering
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasil, 88020-210
- Rekruttering
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85224
- Rekruttering
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Rekruttering
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles, California, Forente stater, 90067
- Rekruttering
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- Start Los Angeles /ID# 284999
-
Oxnard, California, Forente stater, 93030
- Rekruttering
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Fullført
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32256
- Rekruttering
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala, Florida, Forente stater, 34474
- Rekruttering
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines, Florida, Forente stater, 33028
- Rekruttering
- Memorial Hospital West /ID# 270313
-
St. Petersburg, Florida, Forente stater, 33701-4732
- Rekruttering
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg, Florida, Forente stater, 33705
- Rekruttering
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach, Florida, Forente stater, 33401
- Rekruttering
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens, Georgia, Forente stater, 30607
- Rekruttering
- University Cancer and Blood Center /ID# 270969
-
Marietta, Georgia, Forente stater, 30060
- Rekruttering
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah, Georgia, Forente stater, 31404
- Fullført
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96819
- Rekruttering
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60607
- Rekruttering
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles, Illinois, Forente stater, 60714
- Rekruttering
- Illinois Cancer Specialists /ID# 274678
-
Peoria, Illinois, Forente stater, 61637-0001
- Rekruttering
- OSF St. Francis Medical Center /ID# 281591
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68506
- Rekruttering
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha, Nebraska, Forente stater, 68130
- Rekruttering
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno, Nevada, Forente stater, 89502
- Rekruttering
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816-4096
- Rekruttering
- Astera Cancer Care /ID# 272359
-
Teaneck, New Jersey, Forente stater, 07666
- Rekruttering
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury, New York, Forente stater, 11590
- Rekruttering
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst, North Carolina, Forente stater, 28374
- Rekruttering
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg, Ohio, Forente stater, 43551
- Rekruttering
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville, Ohio, Forente stater, 43701
- Rekruttering
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre, Pennsylvania, Forente stater, 18840
- Rekruttering
- Guthrie Robert Packer Hospital /ID# 270316
-
York, Pennsylvania, Forente stater, 17403
- Rekruttering
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- Medical University of South Carolina /ID# 273272
-
Greenville, South Carolina, Forente stater, 29607
- Rekruttering
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler, Texas, Forente stater, 75702
- Rekruttering
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden, Utah, Forente stater, 84405
- Rekruttering
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane, Washington, Forente stater, 99208
- Rekruttering
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma, Washington, Forente stater, 98405
- Rekruttering
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
-
-
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem, Israel, 9103102
- Fullført
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava, Central District, Israel, 4428164
- Rekruttering
- Meir Medical Center /ID# 270071
-
Petah Tikva, Central District, Israel, 4941492
- Rekruttering
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5265601
- Rekruttering
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 466-8560
- Rekruttering
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Rekruttering
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe, Hyōgo, Japan, 650-0046
- Rekruttering
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japan, 252-0375
- Rekruttering
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai, Miyagi, Japan, 981-0914
- Rekruttering
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japan, 889-1692
- Rekruttering
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, Japan, 710-8602
- Rekruttering
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda, Shizuoka, Japan, 426-0077
- Rekruttering
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama, Wakayama, Japan, 641-8510
- Rekruttering
- Wakayama Medical University Hospital /ID# 276997
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 101149
- Rekruttering
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350014
- Rekruttering
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530021
- Rekruttering
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Rekruttering
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou, Henan, Kina, 450008
- Rekruttering
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekruttering
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Rekruttering
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710061
- Rekruttering
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi, Shandong, Kina, 276001
- Rekruttering
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi, Xinjiang, Kina, 830011
- Rekruttering
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
Beograd
-
Belgrade, Beograd, Serbia, 11000
- Rekruttering
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade, Beograd, Serbia, 11080
- Rekruttering
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade, Beograd, Serbia, 11000
- Rekruttering
- University Clinical Center Serbia /ID# 270808
-
Belgrade, Beograd, Serbia, 11000
- Rekruttering
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš, Nisavski Okrug, Serbia, 18300
- Rekruttering
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz, Sremski Okrug, Serbia, 21208
- Rekruttering
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac, Sumadijski Okrug, Serbia, 34000
- Rekruttering
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 169611
- Rekruttering
- National Cancer Centre Singapore /ID# 271499
-
Singapore, Central Singapore, Singapore, 119074
- Rekruttering
- National University Hospital /ID# 271700
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Andre navn:
|
|
Eksperimentell: Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Andre navn:
|
|
Eksperimentell: Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Tidsramme: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Tidsramme: Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Tidsramme: Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Tidsramme: Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Tidsramme: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Tidsramme: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
Tidsramme: Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Tidsramme: Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Tidsramme: Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Tidsramme: Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Tidsramme: Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Tidsramme: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
Tidsramme: Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
Tidsramme: Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Tidsramme: Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: ABBVIE INC., AbbVie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- M25-274
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Tilgangskriterier for IPD-deling
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .